---
title: "MediWound Q1 Revenue Declines; Reaffirms 2026 Full-Year Guidance; Stock Up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287865461.md"
description: "MediWound Ltd. reported Q1 2026 revenue of $1.5 million, down 62.5% from $4 million last year, citing BARDA-related revenue and shipment delays. The net loss widened to $3 million, with an adjusted EBITDA loss of $7 million. The company reaffirmed its 2026 revenue guidance of $24-26 million, supported by government contracts. Shares fell 14.09% to $14.33 but rose 3.42% in after-hours trading to $14.82."
datetime: "2026-05-28T05:45:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287865461.md)
  - [en](https://longbridge.com/en/news/287865461.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287865461.md)
---

# MediWound Q1 Revenue Declines; Reaffirms 2026 Full-Year Guidance; Stock Up

(RTTNews) - MediWound Ltd. (MDWD) reported its financial results for the first quarter of 2026, reflecting a revenue decline, and reaffirmed the full-year revenue guidance.

**Company Profile**

MediWound is a biopharmaceutical company focused on developing solutions for tissue repair and regeneration. The company markets FDA-approved NexoBird biologic for the enzymatic removal of eschar burns in patients with thermal burns. The firm is also developing EscharEx, a late-stage investigational product for the debridement of chronic wounds.

**First Quarter Results**

The total revenue for the first quarter of 2026 totalled $1.5 million, representing a 62.5% decrease from $4 million in the year-ago quarter. The company states that the decrease is attributable to BARDA-related revenues and postponed shipments related to the regional conflict.

MediWound reported a wider net loss of $3 million, or $0.23 per share, from a net loss of $0.7 million, or $0.07 per share, in the prior year.

Adjusted EBITDA loss expanded to $7 million this quarter, compared to a loss of $4 million in the same period last year.

As of March 31, 2026, cash, cash equivalents, and deposits totalled $45 million.

**2026 Guidelines**

The company reaffirmed its guidance for full-year 2026, projecting revenue growth of $24 million to $26 million, primarily supported by expected revenue from government-related development services in the second half of 2026.

MDWD has traded between $14.9 and $22.5 over the last year. Shares closed down 14.09% on Wednesday at $14.33.

**Operational Milestones Ahead**

Enrollment continues for the EscharEx global Phase III VALUE study in venous leg ulcers, targeting 216 patients across 40 sites in the U.S, Europe, and Israel. The pre-specified interim assessment and enrollment completion are expected by the end of the first quarter of 2027.

Medline joined the EscharEx clinical development program through a research collaboration agreement with MediWound.

Vericel was awarded a ten-year BARDA contract for NexoBird procurement at a value of up to $197 million. The procurement activity is expected to begin in the second half of 2026. MDWD is trading up 3.42% to $14.82 in the after hours market.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [MDWD.US](https://longbridge.com/en/quote/MDWD.US.md)
- [MDLN.US](https://longbridge.com/en/quote/MDLN.US.md)
- [VCEL.US](https://longbridge.com/en/quote/VCEL.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [Cognizant announces BRL 1.14 per unit distribution for Q3 2026](https://longbridge.com/en/news/294398291.md)
- [Beyond Oil to Report Second Quarter 2026 Financial Results on August 14, 2026 | BEOLF Stock News](https://longbridge.com/en/news/294260282.md)
- [Okeanis Eco Tankers to webcast Q2 2026 results update](https://longbridge.com/en/news/294410496.md)
- [ERG announces availability of H1 2026 interim financial report](https://longbridge.com/en/news/294572882.md)